Published in Br J Cancer on June 09, 2009
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 3.62
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med (2012) 1.85
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. PLoS One (2015) 1.06
bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford) (2013) 1.05
CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res (2011) 0.90
Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PLoS One (2014) 0.84
Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling. PLoS One (2014) 0.82
UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy. Int J Clin Exp Pathol (2013) 0.81
Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biol Cell (2015) 0.80
Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer. PLoS One (2014) 0.78
Prognostic significance of PLIN1 expression in human breast cancer. Oncotarget (2016) 0.75
Co-expression network analysis identified six hub genes in association with progression and prognosis in human clear cell renal cell carcinoma (ccRCC). Genom Data (2017) 0.75
The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int (2017) 0.75
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
Basic Medical Research Award. The ubiquitin system. Nat Med (2000) 4.03
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast (2008) 2.96
The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol (2005) 2.86
The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci (2009) 1.82
Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene (2004) 1.82
Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer. Bioinformatics (2007) 1.50
UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res (2003) 1.49
Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol (2003) 1.43
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res (2002) 1.42
Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat (2006) 1.36
Ubiquitin and breast cancer. Oncogene (2004) 1.26
The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans (2003) 1.18
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res (2005) 1.13
UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer (2007) 1.10
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev (2003) 1.09
Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics (2006) 1.08
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther (2006) 1.07
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol (2007) 1.04
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat (2007) 1.00
The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res (2002) 0.99
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat (2008) 0.87
The UPS: a promising target for breast cancer treatment. BMC Biochem (2008) 0.85
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Haemochromatosis and HLA-H. Nat Genet (1996) 2.70
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer (1981) 2.23
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia (2003) 2.07
Interleukin-6 in human multiple myeloma. Blood (1995) 1.95
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 1.93
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat (2001) 1.80
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood (1990) 1.75
Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia (2006) 1.67
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood (1999) 1.65
IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. Eur J Immunol (1999) 1.64
Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood (2001) 1.62
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol (1989) 1.60
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol (2007) 1.59
P53 deletion is not a frequent event in multiple myeloma. Br J Haematol (1999) 1.57
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging (2006) 1.53
Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol (1993) 1.47
The impact of nonvisualization of sentinel nodes on lymphoscintigraphy in breast cancer. Ann Surg Oncol (2005) 1.45
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw (1991) 1.42
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol (1999) 1.42
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood (1994) 1.37
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum (1990) 1.32
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum (1992) 1.29
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol (1983) 1.28
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood (1984) 1.26
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol (2009) 1.26
Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis (2004) 1.25
p53 and RAS gene mutations in multiple myeloma. Oncogene (1992) 1.24
B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases. Am J Med (1987) 1.23
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. Cancer Res (1999) 1.23
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med (1994) 1.22
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia (1998) 1.22
Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol (2009) 1.21
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood (1995) 1.20
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol (2006) 1.20
Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood (1997) 1.19
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol (1999) 1.19
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol (1992) 1.17
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. Blood (1999) 1.16
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer (2009) 1.14
Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.14
Mutations of the p53 gene in human myeloma cell lines. Oncogene (1992) 1.13
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer (2011) 1.13
The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw (2000) 1.12
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am (1992) 1.12
Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res (1995) 1.10
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood (1996) 1.10
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol (2003) 1.10
Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol (2000) 1.10
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res (1998) 1.09
Significant impact of survivin on myeloma cell growth. Leukemia (2007) 1.08
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol (2000) 1.07
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood (1995) 1.06
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol (1991) 1.05
Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys (2001) 1.05
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res (1998) 1.04
Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood (1995) 1.04
Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer (2010) 1.04
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer (1992) 1.04
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res (1999) 1.04
CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res (1998) 1.02
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol (2004) 1.01
Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant (1999) 1.01
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer (1999) 1.01
Localized Plasmacytomas. Clin Haematol (1982) 1.00
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia (1999) 1.00
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia (2011) 0.99
Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) (1999) 0.98
Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma. Leukemia (2003) 0.98
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol (2012) 0.98
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol (2000) 0.98
Hemoptysis and pneumomediastinum after breath-hold diving in shallow water: a case report. Undersea Hyperb Med (2011) 0.97
Autoimmunity to human thyroglobulin. Respective epitopic specificity patterns of anti-human thyroglobulin autoantibodies in patients with Sjögren's syndrome and patients with Hashimoto's thyroiditis. Arthritis Rheum (1991) 0.97
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer (2004) 0.96
Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol (1999) 0.95
Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis (2012) 0.95
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer (2008) 0.95
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol (1991) 0.95
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer (2012) 0.95
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol (2001) 0.95
Cytokine gene expression in human multiple myeloma. Br J Haematol (1993) 0.94
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer (2009) 0.93
Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. Br J Haematol (1990) 0.93